Dr Raghav on a Phase 2 Study of ABBV-400 Plus Fluorouracil, Folinic Acid, and Bevacizumab in Pretreated Metastatic CRC

Kanwal P.S. Raghav, MD, MBBS, clinical medical director, Division of Ambulatory Treatment Centers (MDACC), and associate professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a phase 2 study (NCT06107413) of ABBV-400 plus fluorouracil (5-FU), folinic acid, and bevacizumab (Avastin) in pretreated patients with metastatic colorectal cancer.